{"entity":{"id":"nct06735131","kind":"trial","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","aka":[],"tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting.","summary":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC is a phase 2, interventional study registered as NCT06735131 by Sun Yat-sen University, with a registry enrolment figure of 60 participants, started 2024-12-20 and due to reach its primary completion in 2026-07. Interventions recorded: radiotherapy 5 Gy × 5 fractions, once a day; radiotherapy 8 Gy × 5 fractions, once a day; radiotherapy 8 Gy × 3 fractions, once every other day; radiotherapy 10 Gy× 3 fractions, once every other day; radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy); Toripalimab; chemotherapy regimen selected by the investigator. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: \"Inoperable locally advanced/metastatic triple-negative breast cancer (defined as ER and PR \\<1%; and HER2 negative as IHC 0 or IHC 1+, or IHC 2+ but negative upon fluorescence in situ hybridization (FISH) testing)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06735131","url":"https://clinicaltrials.gov/study/NCT06735131"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06735131","phase":"2","setting":"A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer","sponsor":"Sun Yat-sen University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06735131/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}